Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Status:
Recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
Advanced small cell ovarian carcinomas are rare and have a very poor prognosis affecting a
young population. The objective of this study is to increase the efficacy of the initial
chemotherapy by providing immunotherapy and to be able to offer to more patients the
possibility of benefiting from an intensification of chemotherapy, which is a major
prognostic factor in this population.